PMID- 35832520
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231221
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2022
DP  - 2022
TI  - The Influence of Ixeris sonchifolia Hance Injection Combined with Isosorbide 
      Mononitrate in Patients with Coronary Heart Disease and Diabetes.
PG  - 7503380
LID - 10.1155/2022/7503380 [doi]
LID - 7503380
AB  - OBJECTIVE: To evaluate the influence of Ixeris sonchifolia Hance injection 
      combined with isosorbide mononitrate in patients with coronary heart disease 
      (CHD) and diabetes. METHODS: 60 patients with CHD and diabetes mellitus admitted 
      to our hospital between January 2019 and June 2020 were recruited and assigned 
      via the random number table method at a ratio of 1 : 1 to receive either 
      isosorbide mononitrate treatment (control group) or Ixeris sonchifolia Hance 
      injection plus isosorbide mononitrate treatment (observation group). Outcome 
      measures included left ventricular end diastolic pressure (LVEDP), left 
      ventricular end systolic volume (LVESV), left ventricular function (LVEF), brain 
      natriuretic peptide (BNP), and the total treatment efficiency. RESULTS: The two 
      groups had similar LVEDP, LVESV, and LVEF before treatment (p > 0.05). After 
      treatment, the LVEDP and LVESV of the two groups declined (p < 0.05), whereas 
      LVEF increased (p < 0.05), with lower LVEDP and LVESV and higher LVEF in the 
      observation group than in the control group (p < 0.05). Before treatment, there 
      were no significant differences in the BNP levels between the two groups (p > 
      0.05). After treatment, the observation group had a more significant reduction in 
      the BNP levels versus the observation group (p < 0.05). The observation group 
      showed a higher treatment efficacy than the control group (p < 0.05). CONCLUSION: 
      Ixeris sonchifolia Hance plus isosorbide mononitrate may offer a viable 
      alternative in the treatment of patients with CHD and diabetes mellitus. Future 
      trials are, however, required prior to clinical promotion.
CI  - Copyright (c) 2022 Li Zhang and Xiaomin Qin.
FAU - Zhang, Li
AU  - Zhang L
AD  - Wuhu Fifth People's Hospital, Wuhu, China.
FAU - Qin, Xiaomin
AU  - Qin X
AUID- ORCID: 0000-0002-1362-9866
AD  - Wuhu Fifth People's Hospital, Wuhu, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20220704
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
RIN - Evid Based Complement Alternat Med. 2023 Dec 13;2023:9878906. PMID: 38125156
PMC - PMC9273379
COIS- The authors declare that they have no conflicts of interest.
EDAT- 2022/07/15 06:00
MHDA- 2022/07/15 06:01
PMCR- 2022/07/04
CRDT- 2022/07/14 02:24
PHST- 2022/03/22 00:00 [received]
PHST- 2022/04/25 00:00 [revised]
PHST- 2022/04/30 00:00 [accepted]
PHST- 2022/07/14 02:24 [entrez]
PHST- 2022/07/15 06:00 [pubmed]
PHST- 2022/07/15 06:01 [medline]
PHST- 2022/07/04 00:00 [pmc-release]
AID - 10.1155/2022/7503380 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2022 Jul 4;2022:7503380. doi: 
      10.1155/2022/7503380. eCollection 2022.